Indian pharmaceutical companies start developing generic Wegovy

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

Indian pharmaceutical companies start developing generic Wegovy

• Shocking! All existing AIDS vaccine developments have failed 
• Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
• CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

Weight loss drug market potential enormous: Indian pharmaceutical companies start developing generic Wegovy

In order to carve out a share in the rapidly growing weight loss drug market, Indian pharmaceutical companies have begun developing generic versions of the popular drug Wegovy. Executives from the world’s largest generic drug manufacturers, such as Sun Pharma, Cipla, Dr. Reddy’s, and Lupin, have all stated that they have started developing generic versions of Wegovy.

Due to strong market demand, Novo Nordisk’s (NVO.US) weight loss drug Wegovy has consistently been in short supply, as have competitors Eli Lilly’s (LLY.US) Zepbound and Mounjaro. Analysts suggest that this move by Indian pharmaceutical companies could significantly improve global access to weight loss drugs and greatly reduce the price of these medications.

Vishal Manchanda, an analyst at Systematix, said, “We expect sales of weight loss drugs to increase several times when the patent for Wegovy expires, but that’s a few years away. Generic drug manufacturers will offer these drugs at lower prices.”

It is reported that the patent for Wegovy will expire in China in 2026, in Japan and Europe in 2031, and in the United States in 2032. It is currently unclear when the patent for Wegovy will expire in India.

India’s weight loss drug market has enormous potential. Data shows that India has a high obesity rate, especially among women, and is home to the second-highest number of type 2 diabetes patients in the world. According to the World Obesity Federation Atlas, by 2035, around 11% of adults in India will be obese.

According to estimates from market research firm experts, the Indian diabetes drug market alone will reach 316 billion rupees ($3.81 billion) by 2023, and is expected to reach 1.2 trillion rupees ($14.48 billion) in the next decade.

Indian pharmaceutical companies start developing generic Wegovy

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.